PROK
ProKidney Corp.
$1.83
$0.00(0.00%)
38
Overall
40
Value
36
Tech
--
Quality
Market Cap
$540.43M
Volume
998.21K
52W Range
$0.46 - $7.13
Target Price
$5.50
Company Overview
| Mkt Cap | $540.43M | Price | $1.83 |
| Volume | 998.21K | Change | +0.00% |
| P/E Ratio | -8.8 | Open | $1.79 |
| Revenue | $76.0K | Prev Close | $1.83 |
| Net Income | $-61.2M | 52W Range | $0.46 - $7.13 |
| Div Yield | N/A | Target | $5.50 |
| Overall | 38 | Value | 40 |
| Quality | -- | Technical | 36 |
No chart data available
About ProKidney Corp.
ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. The company also develops a cryopreserved version of rilparencel that allows for long-term product preservation to be used in Phase 2 and 3 trials of rilparencel. ProKidney Corp. founded in 2015 and is based in Winston-Salem, North Carolina.
Latest News
Guggenheim Sticks to Its Buy Rating for ProKidney (PROK)
TipRanks Auto-Generated Intelligence Newsdesk•20 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | PROK | $1.83 | 0% | 998.21K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |